Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mosaica Medicines Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, meaning that each active case is under the review of a different individual. The portfolio is also spread across 2 distinct art units, indicating that the company's biotechnology filings are technically diverse enough to be classified into separate specialized groups. LAURA LYNNE STOCKTON is the busiest examiner for the company, managing 1 pending office action.
Since there are 2 pending actions in total, each of the distinct examiners is responsible for a single action. Practitioners must tailor their arguments to the individual preferences of different examiners while also navigating the specific procedural standards of 2 distinct art units. This structure suggests that the outcomes of the pending office actions are likely independent of each other, as there is no overlap in personnel or technical groups. The presence of multiple distinct art units within the Biotechnology & Pharmaceuticals sector highlights the varied nature of the company's current research and development efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18890248 | INHIBITORS OF MEK KINASE | STOCKTON, LAURA LYNNE | — |
| 18266793 | KINASE INHIBITORS AND USES THEREOF | ENGLISH, CONNOR KENNEDY | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18890248 | INHIBITORS OF MEK KINASE | STOCKTON, LAURA LYNNE | 1626 | DP | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18266793 | KINASE INHIBITORS AND USES THEREOF | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Jun 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMosaica Medicines Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Laura Lynne Stockton has the most, with 1 of Mosaica Medicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
